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CASE HISTORY
A 45-year-old man, known to be hypertensive and 
with a history of smoking (5 cigarettes a day for 18 
years), presented to Tygerberg Hospital with peripheral 
vascular disease necessitating bilateral amputations at 
the knee. The patient had no other significant medical 
disorders and no previous history of tuberculosis (TB), 
and consumed alcohol socially. He had been well before 
this admission, with no previous medical or surgical 
admissions. The findings on general and systemic 
examination were normal and no lumps were noted on 
the body. 
The patient was tested for HIV as part of his surgical 
work-up and was found to be positive with a CD4 
count of 152 cells/µl. He was commenced on ARVs: 
stavudine (D4T) 30 mg 12-hourly, lamivudine (3TC) 150 
mg 12-hourly and efavirenz (EFV) 600 mg at night. He 
underwent successful above-knee amputations and 
was subsequently followed up at the Tygerberg Hospital 
Infectious Disease Clinic approximately 1 month later.
The patient was doing well and reported no problems 
or side-effects from the ARVs. The stumps were clean 
and findings on a thorough physical examination were 
normal. No lumps were detected on the patient’s body 
at this visit. The patient had no symptoms of TB, but a 
chest radiograph revealed infiltrates in the right upper 
zone. At this stage we were still awaiting sputum 
results from his initial admission. Two weeks later 
(approximately 6 weeks after ARV initiation) drug-
susceptible TB was diagnosed on sputum culture. TB 
treatment was immediately commenced.
The patient returned for a follow-up visit after a further 
2 weeks complaining of multiple lumps on the trunk 
and abdomen. Physical examination revealed multiple 
soft, mobile, non-tender nodules on the abdomen (Fig. 
1), measuring approximately 2×2 cm. A fine-needle 
aspirate and excision biopsy confirmed that these were 
lipomas. A fasting lipogram revealed a total cholesterol 
level of 5.7 mmol/l, a triglyceride level of 2.0 mmol/l, a 
high-density lipoprotein (HDL) cholesterol level of 1.2 
mmol/l and a low-density lipoprotein (LDL) cholesterol 
level of 3.6 mmol/l.
The patient was counselled regarding his condition and 
continued on his anti-TB treatment and ARVs. He was 
started on the appropriate medical management for his 
dyslipidaemia and given appropriate dietary advice.
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Lipodystrophy is a complication of patients on antiretroviral (ARV) medication; however, it is commonest in 
patients on long-term treatment and those on protease inhibitor (PI) regimens.1,2 We present a rare case of 
atypical lipodystrophy, presenting as multiple subcutaneous lipomas, in a patient who had been on a non-PI 
ARV regimen for 6 weeks.
Fig. 1. Multiple lipomas on the patient’s abdomen.
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DISCuSSIOn
Lipodystrophy encompasses both lipo-atrophy 
and lipohypertrophy. Lipo-atrophy presents as 
subcutaneous fat wasting in the face and peripheries, 
whereas lipohypertrophy occurs as fat accumulation 
in the abdomen, breast and dorso-cervical region.2,3 
Lipodystrophy can be associated with hyperlipidaemia 
and insulin resistance, which constitute the 
lipodystrophy syndrome.3 The commonest class of 
ARVs to cause lipodystrophy is the PIs.1-3 These agents 
are commonly used in second-line regimens in ARV 
treatment in South Africa.
This patient presented with multiple subcutaneous 
lipomas on the abdomen 6 weeks after commencing 
ARVs and approximately 2 weeks after starting TB 
treatment. This was an extremely interesting and yet 
perplexing presentation. Diagnosis of a novel immune 
reconstitution inflammatory syndrome phenomenon or 
a cutaneous lymphoma was considered, but the patient 
was clinically well, histological examination confirmed 
a lipoma with no inflammatory cell infiltrate, and 
biopsies of the lesions did not culture TB or any other 
bacterial organism. 
The reason for the acute onset of the lipomas, and in 
a patient not on a PI, eludes the authors. The patient’s 
background medical condition of hypertension and 
peripheral vascular disease may have contributed to 
the development of the lipomas. Google Scholar and 
Pubmed searches in the English language revealed only 
1 other case in which subcutaneous lipomas developed 
on a regimen without PIs.4 That patient had been on 
3TC, tenofovir and EFV. It is unclear whether EFV, 3TC 
or both contributed to the lipomas in our case, as that 
patient was also on both these agents. 
Most patients who develop lipodystrophy syndrome 
while on PIs are switched to a non-nucleoside reverse 
transcriptase inhibitor, usually with improvement in 
their dyslipidaemia.4,5 Owing to the unique nature of 
our case, with no evidence base to guide treatment, it 
was decided to continue the regimen of 3TC, D4T and 
EFV.
It is important that clinicians are aware of this rare and 
atypical form of lipodystrophy, which can apparently 
occur in patients taking nucleoside reverse transcriptase 
inhibitors and non-nucleoside reverse transcriptase 
inhibitors. If it occurs, the most important issue is 
to counsel the patient regarding lipomas and their 
benign nature and that they should remain compliant 
on treatment. It would be useful if a registry could be 
created to document such atypical adverse effects of 
ARVs in order for research to be conducted which may 
prevent such phenomena and guide us on appropriate 
drug changes if and when required.  
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